For example, new vessel growth driven by alternative pro-angiogenic growth factors, such as FGF2, HGF or IL-8, may drive acquired resistance to TKIs in RCC or neuroendocrine tumours [137, 138, 140, 144]. The gene discussed is HGF; the disease is neuroendocrine neoplasm.